Feasibility of corifollitropin alfa/GnRH antagonist protocol combined with GnRH agonist triggering and freeze-all strategy in polycystic ovary syndrome patients

Jiann Loung Hwang, Shee Uan Chen, Hen Ju Chen, Hsin Fu Chen, Yu Shih Yang, Chin Hao Chang, Kok Min Seow, Chii Ruey Tzeng, Yu Hung Lin

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Background/Purpose: The long-acting corifollitropin alfa is comparable to FSH in terms of pregnancy outcomes in normal responders and poor responders. Corifollitropin alfa has never been studied in polycystic ovary syndrome (PCOS) patients because of concerns of excessive ovarian stimulation and ovarian hyperstimulation syndrome (OHSS). The purpose of the study was to evaluate if corifollitropin alfa can be used in PCOS patients. Methods: Forty PCOS patients who were going to undergo in vitro fertilization were enrolled in this study. A single injection of corifollitropin alfa was administered on cycle day 2 or day 3. From stimulation day 8 onwards, daily FSH was administered until the day of final oocyte maturation. Cetrorelix was administered from stimulation day 5 to prevent premature LH surge. Final oocyte maturation was triggered by: acetate. All embryos were cryopreserved and replaced in subsequent cycles. Results: All 40 patients were subjected to oocyte retrieval, and none developed moderate or severe ovarian hyperstimulation syndrome (0%, 95% CI 0-0.088). For each patient, an average of 23.4 (±7.4; 95% CI 21.0-25.7) oocytes were retrieved and a mean of 11.7 (±6.4; 95% CI 9.6-13.8) embryos were frozen. Mean serum estradiol level on the day of GnRHa triggering was 7829.9 pg/ml (±3297; 95% CI 6775-8885). The cumulated ongoing pregnancy rate after 3 frozen-thawed embryo transfers was 75.0% (95% CI 61.6%-88.4%). Conclusion: The results suggest that corifollitropin alfa/GnRH antagonist protocol can be used in PCOS patients, in combination with GnRHa triggering and embryo cryopreservation.

Original languageEnglish
JournalJournal of the Formosan Medical Association
DOIs
Publication statusAccepted/In press - 2017
Externally publishedYes

Fingerprint

Polycystic Ovary Syndrome
Gonadotropin-Releasing Hormone
Ovarian Hyperstimulation Syndrome
Oocytes
Embryonic Structures
Oocyte Retrieval
Ovulation Induction
Embryo Transfer
Cryopreservation
Pregnancy Rate
Fertilization in Vitro
Pregnancy Outcome
follicle stimulating hormone, human, with HCG C-terminal peptide
Estradiol
Acetates
Injections
Serum

Keywords

  • Corifollitropin alfa
  • Cryopreservation
  • GnRH agonist
  • Polycystic ovary syndrome

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Feasibility of corifollitropin alfa/GnRH antagonist protocol combined with GnRH agonist triggering and freeze-all strategy in polycystic ovary syndrome patients. / Hwang, Jiann Loung; Chen, Shee Uan; Chen, Hen Ju; Chen, Hsin Fu; Yang, Yu Shih; Chang, Chin Hao; Seow, Kok Min; Tzeng, Chii Ruey; Lin, Yu Hung.

In: Journal of the Formosan Medical Association, 2017.

Research output: Contribution to journalArticle

Hwang, Jiann Loung ; Chen, Shee Uan ; Chen, Hen Ju ; Chen, Hsin Fu ; Yang, Yu Shih ; Chang, Chin Hao ; Seow, Kok Min ; Tzeng, Chii Ruey ; Lin, Yu Hung. / Feasibility of corifollitropin alfa/GnRH antagonist protocol combined with GnRH agonist triggering and freeze-all strategy in polycystic ovary syndrome patients. In: Journal of the Formosan Medical Association. 2017.
@article{20a417fc498c4fb786ca4aa47e870155,
title = "Feasibility of corifollitropin alfa/GnRH antagonist protocol combined with GnRH agonist triggering and freeze-all strategy in polycystic ovary syndrome patients",
abstract = "Background/Purpose: The long-acting corifollitropin alfa is comparable to FSH in terms of pregnancy outcomes in normal responders and poor responders. Corifollitropin alfa has never been studied in polycystic ovary syndrome (PCOS) patients because of concerns of excessive ovarian stimulation and ovarian hyperstimulation syndrome (OHSS). The purpose of the study was to evaluate if corifollitropin alfa can be used in PCOS patients. Methods: Forty PCOS patients who were going to undergo in vitro fertilization were enrolled in this study. A single injection of corifollitropin alfa was administered on cycle day 2 or day 3. From stimulation day 8 onwards, daily FSH was administered until the day of final oocyte maturation. Cetrorelix was administered from stimulation day 5 to prevent premature LH surge. Final oocyte maturation was triggered by: acetate. All embryos were cryopreserved and replaced in subsequent cycles. Results: All 40 patients were subjected to oocyte retrieval, and none developed moderate or severe ovarian hyperstimulation syndrome (0{\%}, 95{\%} CI 0-0.088). For each patient, an average of 23.4 (±7.4; 95{\%} CI 21.0-25.7) oocytes were retrieved and a mean of 11.7 (±6.4; 95{\%} CI 9.6-13.8) embryos were frozen. Mean serum estradiol level on the day of GnRHa triggering was 7829.9 pg/ml (±3297; 95{\%} CI 6775-8885). The cumulated ongoing pregnancy rate after 3 frozen-thawed embryo transfers was 75.0{\%} (95{\%} CI 61.6{\%}-88.4{\%}). Conclusion: The results suggest that corifollitropin alfa/GnRH antagonist protocol can be used in PCOS patients, in combination with GnRHa triggering and embryo cryopreservation.",
keywords = "Corifollitropin alfa, Cryopreservation, GnRH agonist, Polycystic ovary syndrome",
author = "Hwang, {Jiann Loung} and Chen, {Shee Uan} and Chen, {Hen Ju} and Chen, {Hsin Fu} and Yang, {Yu Shih} and Chang, {Chin Hao} and Seow, {Kok Min} and Tzeng, {Chii Ruey} and Lin, {Yu Hung}",
year = "2017",
doi = "10.1016/j.jfma.2017.05.009",
language = "English",
journal = "Journal of the Formosan Medical Association",
issn = "0929-6646",
publisher = "Elsevier Science Publishers B.V.",

}

TY - JOUR

T1 - Feasibility of corifollitropin alfa/GnRH antagonist protocol combined with GnRH agonist triggering and freeze-all strategy in polycystic ovary syndrome patients

AU - Hwang, Jiann Loung

AU - Chen, Shee Uan

AU - Chen, Hen Ju

AU - Chen, Hsin Fu

AU - Yang, Yu Shih

AU - Chang, Chin Hao

AU - Seow, Kok Min

AU - Tzeng, Chii Ruey

AU - Lin, Yu Hung

PY - 2017

Y1 - 2017

N2 - Background/Purpose: The long-acting corifollitropin alfa is comparable to FSH in terms of pregnancy outcomes in normal responders and poor responders. Corifollitropin alfa has never been studied in polycystic ovary syndrome (PCOS) patients because of concerns of excessive ovarian stimulation and ovarian hyperstimulation syndrome (OHSS). The purpose of the study was to evaluate if corifollitropin alfa can be used in PCOS patients. Methods: Forty PCOS patients who were going to undergo in vitro fertilization were enrolled in this study. A single injection of corifollitropin alfa was administered on cycle day 2 or day 3. From stimulation day 8 onwards, daily FSH was administered until the day of final oocyte maturation. Cetrorelix was administered from stimulation day 5 to prevent premature LH surge. Final oocyte maturation was triggered by: acetate. All embryos were cryopreserved and replaced in subsequent cycles. Results: All 40 patients were subjected to oocyte retrieval, and none developed moderate or severe ovarian hyperstimulation syndrome (0%, 95% CI 0-0.088). For each patient, an average of 23.4 (±7.4; 95% CI 21.0-25.7) oocytes were retrieved and a mean of 11.7 (±6.4; 95% CI 9.6-13.8) embryos were frozen. Mean serum estradiol level on the day of GnRHa triggering was 7829.9 pg/ml (±3297; 95% CI 6775-8885). The cumulated ongoing pregnancy rate after 3 frozen-thawed embryo transfers was 75.0% (95% CI 61.6%-88.4%). Conclusion: The results suggest that corifollitropin alfa/GnRH antagonist protocol can be used in PCOS patients, in combination with GnRHa triggering and embryo cryopreservation.

AB - Background/Purpose: The long-acting corifollitropin alfa is comparable to FSH in terms of pregnancy outcomes in normal responders and poor responders. Corifollitropin alfa has never been studied in polycystic ovary syndrome (PCOS) patients because of concerns of excessive ovarian stimulation and ovarian hyperstimulation syndrome (OHSS). The purpose of the study was to evaluate if corifollitropin alfa can be used in PCOS patients. Methods: Forty PCOS patients who were going to undergo in vitro fertilization were enrolled in this study. A single injection of corifollitropin alfa was administered on cycle day 2 or day 3. From stimulation day 8 onwards, daily FSH was administered until the day of final oocyte maturation. Cetrorelix was administered from stimulation day 5 to prevent premature LH surge. Final oocyte maturation was triggered by: acetate. All embryos were cryopreserved and replaced in subsequent cycles. Results: All 40 patients were subjected to oocyte retrieval, and none developed moderate or severe ovarian hyperstimulation syndrome (0%, 95% CI 0-0.088). For each patient, an average of 23.4 (±7.4; 95% CI 21.0-25.7) oocytes were retrieved and a mean of 11.7 (±6.4; 95% CI 9.6-13.8) embryos were frozen. Mean serum estradiol level on the day of GnRHa triggering was 7829.9 pg/ml (±3297; 95% CI 6775-8885). The cumulated ongoing pregnancy rate after 3 frozen-thawed embryo transfers was 75.0% (95% CI 61.6%-88.4%). Conclusion: The results suggest that corifollitropin alfa/GnRH antagonist protocol can be used in PCOS patients, in combination with GnRHa triggering and embryo cryopreservation.

KW - Corifollitropin alfa

KW - Cryopreservation

KW - GnRH agonist

KW - Polycystic ovary syndrome

UR - http://www.scopus.com/inward/record.url?scp=85027710552&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85027710552&partnerID=8YFLogxK

U2 - 10.1016/j.jfma.2017.05.009

DO - 10.1016/j.jfma.2017.05.009

M3 - Article

JO - Journal of the Formosan Medical Association

JF - Journal of the Formosan Medical Association

SN - 0929-6646

ER -